| DC73054 |
MAT-POS-e194df51-1 |
MAT-POS-e194df51-1 is potent, selective and noncovalent SARS-CoV-2 main protease (SARS-CoV-2 Mpro) inhibitor with IC50 of 36.8 nM, shows antiviral activity with EC50 of 64 nM in A549-ACE2-TMPRSS2 cells. |
|
| DC73055 |
MDOLL-0229 |
MDOLL-0229 is a selective small molecule inhibitor for SARS-CoV-2 Mac1 with IC50 of 2.1 uM, inhibits coronavirus replication. |
|
| DC73056 |
MI-30 |
MI-30 (SARS-CoV-2 Mpro inhibitor MI-30) is a potent, selective SARS-CoV-2 Mpro inhibitor with IC50 of 17.2 nM. |
|
| DC73057 |
MK-7845 |
MK-7845 is a potent, reversible covalent SARS-CoV-2 3CLPro inhibitor with IC50 of 8.7 nM, inhibits wild-type SARS-CoV-2 3CLPro in SARS-CoV-2 reporter replicon assay in A549 cells with IC50 of 15 nM. |
|
| DC73058 |
ML300 |
ML300 (ML 300) is a potent, selective, noncovalent inhibitor of the SARS-CoV 3CL protease (3CLpro) with IC50 of 4.11 uM, inhibits SARS-CoV-2 3CLpro with IC50 of 4.99 uM. |
|
| DC73059 |
Molnupiravir N-1 |
Molnupiravir N-1 is an impurity chemical of Molnupiravir (EIDD-2801, MK4482), which is anti-SARS-CoV-2 for treatment of COVID-19. |
|
| DC73060 |
MPI3 |
MPI8 is a highly potent SARS-CoV-2 main protease (MPro) inhibitor with IC50 of 8.5 nM. |
|
| DC73061 |
MPI5 |
MPI8 is a highly potent SARS-CoV-2 main protease (MPro) inhibitor with IC50 of 33 nM, completely prevented the SARS-CoV-2-induced cytopathogenic effect in Vero E6 cells at 2.5-5 uM and A549 cells at 0.16-0.31 uM. |
|
| DC73062 |
MU-UNMC-1 |
MU-UNMC-1 is a potential small-molecule inhibitor of S-RBD and ACE-2 interaction, shows antiviral activity against SARS-CoV-2 with IC50 of 0.67 uM in human bronchial epithelial cells. |
|
| DC73063 |
MU-UNMC-2 |
MU-UNMC-2 is a potential small-molecule inhibitor of S-RBD and ACE-2 interaction, shows antiviral activity against SARS-CoV-2 with IC50 of 1.72 uM in human bronchial epithelial cells. |
|
| DC73064 |
NACE2i
Featured
|
NACE2i is a cell permeable, specific and selective peptide inhibitor of nuclear ACE2, inhibits binding between IMP1α and ACE2 and SARS-CoV-2 viral replication.
NACE2i specifically targets nuclear ACE2 and not other nuclear proteins targeted by the importin pathway.
NACE2i has no impact on ACE2 enzymatic activity.
NACE2i prevents inflammation and macrophage infiltration, and increases NK cell infiltration in bronchioles.
NACE2i treatment increases the levels of the active histone mark, H3K27ac, restores host translation in infected hamster bronchiolar cells, and leads to an enrichment in methylated ACE2 in hamster bronchioles and lung macrophages.
NACE2i has a dual mode of action: suppressing the lethal inflammation in severe COVID-19 and inhibiting viral replication by restoring host translation of anti-viral cytokines. |
|
| DC73065 |
NBCoV1 |
NBCoV1 is a highly potent small molecule viral fusion inhibitor with potential pan-Coronavirus activity (SARS-CoV IC50=17 nM, SARS-CoV-2 IC50=51 nM, MERS-CoV IC50=75 nM, cell-based single-cycle assays). |
|
| DC73066 |
NBCoV2
Featured
|
NBCoV2 is a highly potent small molecule viral fusion inhibitor with potential pan-Coronavirus activity (SARS-CoV IC50=13.8 nM, SARS-CoV-2 IC50=22.8 nM, MERS-CoV IC50=77 nM, cell-based single-cycle assays).
NBCoV2 also has potent antiviral activity against all mutant pseudoviruses carrying single-, double-, or triple-mutations featured in the B.1.1.7 UK, B.1.351 RSA, and B.1.617.2 Delta variants (IC50=30-80 nM).
NBCoV2 completely preventing the induction of any virus-induced CPE (IC100=1.25 uM, SARS-CoV-2 (US_WA-1/2020)).
NBCoV2 bind to the S2 subdomain of the SARS-CoV-2 trimer, thus, inhibits the fusion of CoVs with the cell membran, and is specific for the SARS-CoV-2 S protein. |
|
| DC73067 |
NSC 621601 |
NSC 621601 (Compound Q34) is a potent, specific inhibitor of SARS-CoV-2 cellular entry with IC50 of 15 uM. |
|
| DC73068 |
Olgotrelvir |
Olgotrelvir (STI-1558) is a next-generation antiviral targeting SARS-CoV-2 Mpro and host lysosomal cysteine protease cathepsin L (CTSL) with high antiviral activity, Olgotrelvir is the prodrug of AC1115. |
|
| DC73069 |
P2119 |
P2119 (P-2119) is an anticoronaviruse chemical probe that inhibit SARS-CoV-2 Spike binding to human ACE2 receptor. |
|
| DC73070 |
P2165 |
P2165 (P-2165) is a anticoronaviruse chemical probe that inhibit SARS-CoV-2 Spike binding to human ACE2 receptor. |
|
| DC73071 |
PAV-104 |
PAV-104 (PAV104) is a novel viral assembly inhibitor, shows potent anti-SARS-CoV-2 activity in Calu-3 cells with EC50 of 1.7 nM and EC90 of 23.5 nM, inhibits the oligomerization of the SARS-CoV-2 nucleocapsid. |
|
| DC73072 |
Pomotrelvir |
Pomotrelvir (PBI-0451) is a potent competitive inhibitor of SARS-CoV-2 Mpro (Ki=2.7 nM) with high selectivity against human proteases, inhibits wild-type SARS-CoV-2 Mpro with IC50 of 24 nM. |
|
| DC73073 |
SB27012
Featured
|
SB27012 (SB 27012) is a small molecule PPI inhibitor of the Spike RBD-ACE2 interaction (IC50=7.7 uM in ELISA assays), binds ACE2 (Kd=210 nM) without affecting ACE2 enzymatic activity. |
|
| DC73074 |
SCoV2 Plpro-Probe-7 |
SCoV2 Plpro-Probe-7 is a peptidomimetic activity probe and substrate for SCoV2 PLpro, exhibits excellent sensitivity to wild-type (WT) SCoV2 PLpro, but not to the catalytically inactive mutant, SCoV2 PLproC112S, consists of a fluorogenic HCC conjugated to |
|
| DC73075 |
Simnotrelvir |
Simnotrelvir (SSD8432, SIM0417) is a potent, selective, covalent and orally bioavailable SARS-CoV-2 3C-like protease (3CLpro) inhibitor with IC50 of 9 nM in enzymatic inhibition assays. |
|
| DC73076 |
Titanocene dichloride |
Titanocene dichloride (Cp2 TiCl 2) is an active inhibitor of interaction between SARS-CoV-2 spike (S) protein with the ACE2 receptor (IC50=3.9 uM) |
|
| DC73077 |
TKB245 |
TKB245 (TKB-245) is a potent, specific SARS-CoV-2 Mpro inhibitor with IC50 of 7 nM, exhibits highly potent anti-SARS-CoV-2 activity with EC50 and EC95 values of 0.03 and 0.53 µM, respectively. |
|
| DC73078 |
TKB248 |
TKB248 (TKB-248) is a potent, specific SARS-CoV-2 Mpro inhibitor with IC50 of 74 nM, exhibits highly potent anti-SARS-CoV-2 activity with EC50 and EC95 values of 0.22 and 0.87 µM, respectively. |
|
| DC73079 |
VE607 |
VE607 is a specific small molecule inhibitor that block S protein-ACE2-mediated cellular entry of the SARS-CoV, inhibits pseudovirus entry with EC50 of 3 μM and inhibited SARS-CoV plaque formation with EC50 of 1.6 μM. |
|
| DC73080 |
WNN2048-F004 |
WNN2048-F004 (Compound 4a) is a potent, covalent, nonpeptidomimetic SARS-CoV-2 main protease (Mpro) inhibitor with biochemical IC50 of 103 nM, covalently binds to the substrate-binding pocket (Cys145) of SARS-CoV-2 Mpro. |
|
| DC73081 |
WU-04 |
WU-04 is a highly potent, non-covalent, orally active inhibitor of SARS-CoV-2 3C-like protease (3CLpro) with IC50 of 72 nM, binding Kd of 37 nM. |
|
| DC73082 |
Y180 |
Y180 is a highly potent, selective, covalent, and orally active SARS-CoV-2 main protease (Mpro) inhibitor with IC50 of 8.1 nM in enzymatic assays, binding Ki value of 1 nM. |
|
| DC73083 |
Z222979552 |
Z222979552 is a small molecule non-covalent SARS-CoV-2 Mpro inhibitor with IC50 of 1.0 uM. |
|
